Venezuelan equine encephalitis virus structural polyprotein (VEEV structural proteins)

Venezuelan equine encephalitis virus (VEEV) antigens, specifically the structural proteins E1, E2, and Capsid, are the primary targets for host immune recognition and therapeutic intervention. The E2 glycoprotein is the major surface antigen responsible for binding to host cell receptors, such as LDLRAD3, while the E1 glycoprotein facilitates the fusion of the viral envelope with the host endosomal membrane (UniProt P03316; PubMed: 33353883). These antigens are utilized in the production of vaccines, including the live-attenuated TC-83 and the formalin-inactivated C-84, which are designed to induce neutralizing antibodies (CDC, 2021). VEEV is a highly infectious alphavirus that causes severe neurological disease in humans and equines, making these antigens critical for diagnostic assays and biodefense strategies (NIH, 2023). Current research focuses on developing recombinant subunit vaccines and monoclonal antibodies that target conserved epitopes on the E2 protein to provide broad protection against multiple VEEV lineages (PubMed: 28416505). Safety considerations for targeting these antigens include managing the reactogenicity of live vaccines and ensuring that induced antibodies do not lead to antibody-dependent enhancement of infection.

Other names

VEEV antigensVEEV structural proteinsVEEV polyproteinVEEV E1/E2/C proteinsVenezuelan equine encephalitis virus proteins

Neutralization of viral entry by blocking E2-mediated receptor binding and E1-mediated membrane fusion; induction of antigen-specific B-cell and T-cell immune responses.